|
Lacrimal gland dysfunction is a major cause of dry eye disease
|
|
|
|
|
|
The era of antiaging ophthalmology comes of age: antiaging approach for dry eye treatment.
Tsubota K; Kawashima M; Inaba T; Dogru M; Ogawa Y; Nakamura S; Shinmura K; Higuchi A; Kawakita T.
Ophthalmic Research. 44(3):146-54, 2010.
|
|
|
|
|
|
Aging and dry eye disease.
Ding J; Sullivan DA.
Experimental Gerontology. 47:483, 2012.
|
|
|
|
|
|
The antiaging approach for the treatment of dry eye.
Tsubota K et al;
Cornea. 31: Suppl 1:S3, 2012.
Currently, there is no therapy available to recover lacrimal function to its normal status.
|
|
|
|
|
|
Meibomian Gland Disease: The Role of Gland Dysfunction in Dry Eye Disease.
Chhadva P; Goldhardt R; Galor A.
Ophthalmology. 124 (11S):S20-S26, 2017.
|
|
|
|
|
|
Age-dependent changes in rat lacrimal gland anti-oxidant and vesicular related protein expression profiles.
Batista TM et al.,
Molecular Vision. 18:194-202, 2012.
|
|
|
|
|
|
Emerging strategies for the diagnosis and treatment of meibomian gland dysfunction.
G. Geerling et al.
The Ocular Surface 15: 179e192, 2017
|
|
|
|
|
|
Advances in Functional Restoration of the Lacrimal Glands
Masatoshi Hirayama
IOVS, Special Issue. Vol. 59, No.14, DES175, 2018
|
|
|
|
|
|
Regeneration of Lacrimal Gland Function to Maintain the Health of the Ocular Surface
Tetsuya Kawakita
IOVS, Special Issue. Vol. 59, No. 14, DES170, 2018
|
|
|
|
|
|
Meibomian Gland Dysfunction: Recent Progress Worldwide and in Japan
IOVS, Special Issue. Vol. 59, No. 14, DES88, 2018
|
|
|
|
|
|
Meibomian gland dysfunction is the primary determinant of dry eye symptoms: Analysis of 2346 patients
The Ocular Surface 18: 604–612, 2020
|
|
|
|
|
|
Advantage of AH-201-DE :
|
|
|
1.
|
Dry eye is an aging process of lacrimal gland of eye which is well recognized recently.
|
|
2.
|
AH-201-DE is the first small molecule through antiaging approach for dry eye drug discovery.
|
|
3.
|
AH-201-DE is an endogenous EPO inducer for activating mitochondria biogenesis and hemoglobin production in lacrimal gland.
|
|
4.
|
So far, no effective therapy for dry eye, AH-201-DE can expand the global market for dry eye.
|
|
5.
|
We are on-going the pre-IND meeting to TFDA.
|
|
|
|
|
Global market for dry eye
|
|
|
|
|
|
Transparency Market Research(2018,Jan)
estimates that the dry eye disease market will expand at a CAGR of 4.5% over the forecast period between 2017 and 2025. Escalating at this pace, the market, which had a valuation of US$ 5 billion in 2016 in terms of revenue, is projected to rise to US$ 7,780.0 Mn by 2025.
|
|
|
|
|
|
Ophthalmic Res 44:146, 2010
The Era of Antiaging Ophthalmology Comes of Age: Antiaging Approach for Dry Eye Treatment.
|
|
|
|
|
|
MedEdicus Proceeding from a CME symposium during AAO 2015
Addressing Unmet Needs in Dry Eye Disease.
|
|
|
|
|
|
THE Ocular Surface 14:264, 2016
Targeting the Unmet Need for Dry Eye Treatment
|
|
|
|
|
|
Antiaging approach for dry eye had been highlighted as “comes of age”,
EH-201 is the unique one for recovery the tear gland dysfuction,
instead of current eye drugs most belong to inhibit on dry eye induced inflammation approach.
|
|
|
|
|
|
Age-related alterations in the lacrimal gland of adult albino rat: a light and electron microscopic study.
El-Fadaly AB, El-Shaarawy EA, Rizk AA, Nasralla MM, Shuaib DM
Annals of Anatomy. 196(5):336-51, 2014.
|
|
|
|
|
|
The Effects of Aging on Corneal and Ocular Surface Homeostasis in Mice.
De Silva MEH, Hill LJ, Downie LE, Chinnery HR
Investigative Ophthalmology & Visual Science. 60(7):2705-2715, 2019
|
|
|
|
|
|
Comparative Analysis of Age-Related Changes in Lacrimal Glands and Meibomian Glands of a C57BL/6 Male Mouse Model.
Yoon CH, Ryu JS, Hwang HS, Kim MK
International Journal of Molecular Sciences. 21(11), 2020
|
|
|
|
|
|
Takeda is offloading dry-eye drug Xiidra to Novartis for up to $5.3 billion, including upfront cash $3.4 billion and milestone based follow-up payments in 2019. Novartis gives up on Xiidra‘s EU approval in 2020 June after EMA regulators there raised “major objections” that ” Specifically, the agency concluded that Xiidra hadn't proven effective across different symptoms of dry eye disease. the improvement was not considered clinically significant,”.
Xiidra (Lifitegrast) inhibits an integrin, LFA-1), from binding to ICAM-1. This mechanism down-regulates inflammation mediated by T lymphocytes.
|